Positron-Emission Tomography

• 

  Subject Areas on Research

  • (18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis. 
  • (18)F-Flourodeoxy-Glucose PET/Computed Tomography in Brain Tumors: Value to Patient Management and Survival Outcomes. 
  • (18)F-Fluorothymidine PET-CT for resected malignant gliomas before radiotherapy: tumor extent according to proliferative activity compared with MRI. 
  • (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study. 
  • 18F FDG PET/CT and Head and Neck Cancer: Patient Management and Outcomes. 
  • 18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model. 
  • 18F-FDG PET/CT Metabolic Tumor Volume and Intratumoral Heterogeneity in Pancreatic Adenocarcinomas: Impact of Dual-Time Point and Segmentation Methods. 
  • 18F-FDG PET/CT and lung cancer: value of fourth and subsequent posttherapy follow-up scans for patient management. 
  • 18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients. 
  • 18F-FDG-PET/CT therapy assessment of locally advanced pancreatic adenocarcinoma: impact on management and utilization of quantitative parameters for patient survival prediction. 
  • 18F-florbetapir Positron Emission Tomography-determined Cerebral β-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery. 
  • 18F-fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging of malignant pleural mesothelioma. 
  • 3'-Deoxy-3'-[F-18]fluorothymidine positron emission tomography in patients with recurrent glioblastoma multiforme: comparison with Gd-DTPA enhanced magnetic resonance imaging. 
  • A Case with Purine Nucleoside Phosphorylase Deficiency Suffering from Late-Onset Systemic Lupus Erythematosus and Lymphoma. 
  • A General Cutoff Level Combined With Personalized Dynamic Change of Serum Carcinoembryonic Antigen Can Suggest Timely Use of FDG PET for Early Detection of Recurrent Colorectal Cancer. 
  • A Protocol for Sedation Free MRI and PET Imaging in Adults with Autism Spectrum Disorder. 
  • A case of curative-intent hepatectomy for colon cancer metastatic to the scapula and liver. 
  • A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma. 
  • A novel metric for quantification of homogeneous and heterogeneous tumors in PET for enhanced clinical outcome prediction. 
  • A p-[18F]fluoroethoxyphenyl bicyclic nucleoside analogue as a potential positron emission tomography imaging agent for varicella-zoster virus thymidine kinase gene expression. 
  • A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). 
  • A programmable smoke delivery device for PET imaging with cigarettes containing 11C-nicotine. 
  • A simplified synthesis of the hypoxia imaging agent 2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-[(18)F]pentafluoropropyl)-acetamide ([18F]EF5). 
  • A systematic review of the factors affecting accuracy of SUV measurements. 
  • A technique of using gated-CT images to determine internal target volume (ITV) for fractionated stereotactic lung radiotherapy. 
  • ACR Appropriateness Criteria® Penetrating Trauma-Lower Abdomen and Pelvis. 
  • ACR-ASNR Practice Parameter for Brain PET/CT Imaging Dementia. 
  • ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI. 
  • ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy. 
  • AJR teaching file: incidental breast cancer detected with 18F-FDG PET/CT. 
  • AJR teaching file: left neck mass evaluated by PET/CT. 
  • Ability of positron emission tomography to detect residual neck node disease in patients with head and neck squamous cell carcinoma after definitive chemoradiotherapy. 
  • Accuracy and generalization capability of an automatic method for the detection of typical brain hypometabolism in prodromal Alzheimer disease. 
  • Accuracy of positron emission tomography in identifying hilar (N1) lymph node involvement in non-small cell lung cancer: Implications for stereotactic body radiation therapy. 
  • Accurate event-driven motion compensation in high-resolution PET incorporating scattered and random events. 
  • Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms. 
  • Adaptive planning using positron emission tomography for locally advanced lung cancer: A feasibility study. 
  • Addition of 18F-FDG PET/CT to clinical assessment predicts overall survival in HNSCC: a retrospective analysis with follow-up for 12 years. 
  • Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial. 
  • Adrenal nodules at FDG PET/CT in patients known to have or suspected of having lung cancer: a proposal for an efficient diagnostic algorithm. 
  • Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers. 
  • Altered prefrontal dopaminergic function in chronic recreational ketamine users. 
  • Ameloblastic carcinoma of the mandible with metastasis to the skull and lung: advanced imaging appearance including computed tomography, magnetic resonance imaging and positron emission tomography computed tomography. 
  • American College of Radiology and Society of Nuclear Medicine and Molecular Imaging Joint Credentialing Statement for PET/MR Imaging: Brain. 
  • American Society of Clinical Oncology 2013 top five list in oncology. 
  • Amyloid beta-positive subjects exhibit longitudinal network-specific reductions in spontaneous brain activity. 
  • Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. 
  • Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. 
  • An assessment of the effects of shell cross-linked nanoparticle size, core composition, and surface PEGylation on in vivo biodistribution. 
  • Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines. 
  • Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. 
  • Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value. 
  • Analytical and biological methods for probing the blood-brain barrier. 
  • Aortic regurgitation in Takayasu's arteritis. 
  • Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. 
  • Approach to pediatric epilepsy surgery: State of the art, Part I: General principles and presurgical workup. 
  • Are discordant positron emission tomography and pathological assessments of the mediastinum in non-small cell lung cancer significant? 
  • Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults. 
  • Association between amygdala reactivity and a dopamine transporter gene polymorphism. 
  • Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers. 
  • Association of Cognitive and Behavioral Features Between Adults With Tuberous Sclerosis and Frontotemporal Dementia. 
  • Association of heat production with 18F-FDG accumulation in murine brown adipose tissue after stress. 
  • Associations between dopamine D2 receptor availability and BMI depend on age. 
  • Authors' Reply. 
  • Automated radiochemical synthesis and biodistribution of [¹¹C]l-α-acetylmethadol ([¹¹C]LAAM). 
  • Better late than early: FDG-PET imaging in metastatic renal cell carcinoma. 
  • Brain FDG PET and the diagnosis of dementia. 
  • Brain PET in the diagnosis of Alzheimer's disease. 
  • Brain connectivity and visual attention. 
  • Brain nicotinic acetylcholine receptor availability and response to smoking cessation treatment: a randomized trial. 
  • Brain nicotinic acetylcholine receptor occupancy: effect of smoking a denicotinized cigarette. 
  • Brain trauma, PET scans and forensic complexity. 
  • Can we improve the identification of ventricular scar to guide substrate-based ventricular tachycardia ablation? 
  • Capacity for 5-HT1A-mediated autoregulation predicts amygdala reactivity. 
  • Cardiovascular PET/MR: We need evidence, not hype. 
  • Cerebral Amyloid and Cognition after Surgery: Reply. 
  • Changes in Aβ biomarkers and associations with APOE genotype in 2 longitudinal cohorts. 
  • Changes in brain function occur years before the onset of cognitive impairment. 
  • Characteristic patterns of inter- and intra-hemispheric metabolic connectivity in patients with stable and progressive mild cognitive impairment and Alzheimer's disease. 
  • Characterization of 3-Dimensional PET Systems for Accurate Quantification of Myocardial Blood Flow. 
  • Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors. 
  • Classification and evaluation strategies of auto-segmentation approaches for PET: Report of AAPM task group No. 211. 
  • Clinical Quantification of Myocardial Blood Flow Using PET: Joint Position Paper of the SNMMI Cardiovascular Council and the ASNC. 
  • Clinical Quantification of Myocardial Blood Flow Using PET: Joint Position Paper of the SNMMI Cardiovascular Council and the ASNC. 
  • Clinical imaging of vascular disease in chronic kidney disease. 
  • Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer. 
  • Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland. 
  • Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence. 
  • Clustered Arg–Gly–Asp peptides enhances tumor targeting of nonviral vectors 
  • Cognitive impact of genetic variation of the serotonin transporter in primates is associated with differences in brain morphology rather than serotonin neurotransmission. 
  • Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans. 
  • Colonic schwannoma visualized on FDG PET/CT. 
  • Combined deletion of Glut1 and Glut3 impairs lung adenocarcinoma growth. 
  • Combining multiple FDG-PET radiotherapy target segmentation methods to reduce the effect of variable performance of individual segmentation methods. 
  • Commentary on "Positron Emission Tomography in the Lung" 25 years after publication in the inaugural issue of the Journal of Thoracic Imaging. 
  • Commentary on imaging of bronchogenic carcinoma. 
  • Comparative characteristics of primary hyperparathyroidism in pediatric and young adult patients. 
  • Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models. 
  • Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum. 
  • Concurrent tracking of anatomy and metabolism. 
  • Connect MM Registry: The Importance of Establishing Baseline Disease Characteristics. 
  • Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. 
  • Continuing education course #1: non-invasive imaging as a problem-solving tool and translational biomarker strategy in toxicologic pathology. 
  • Contouring variations and the role of atlas in non-small cell lung cancer radiation therapy: Analysis of a multi-institutional preclinical trial planning study. 
  • Contribution of F-18 FDG PET-CT in the detection of systemic spread of primary central nervous system lymphoma. 
  • Correlation of [18F]-2-fluoro-deoxy-D-glucose positron emission tomography standard uptake values with the cellular composition of stage I nonsmall cell lung cancer. 
  • Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. 
  • Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques. 
  • Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. 
  • Current worldwide nuclear cardiology practices and radiation exposure: results from the 65 country IAEA Nuclear Cardiology Protocols Cross-Sectional Study (INCAPS). 
  • Cutaneous γδ T-cell lymphomas: a spectrum of presentations with overlap with other cytotoxic lymphomas. 
  • Deformable registration of preoperative PET/CT with postoperative radiation therapy planning CT in head and neck cancer. 
  • Detection of primary breast carcinoma with a dedicated, large-field-of-view FDG PET mammography device: initial experience. 
  • Development of Novel ¹⁸ F-PET Agents for Tumor Hypoxia Imaging. 
  • Diagnosing pulmonic valve infective endocarditis with positron emission tomography-CT. 
  • Diagnostic Accuracy of Follow-Up FDG PET or PET/CT in Patients With Head and Neck Cancer After Definitive Treatment: A Systematic Review and Meta-Analysis. 
  • Diagnostic accuracy of noninvasive testing: necessary but insufficient. 
  • Differential regional decline in dopamine receptor availability across adulthood: Linear and nonlinear effects of age. 
  • Digital anthropomorphic phantoms of non-rigid human respiratory and voluntary body motion for investigating motion correction in emission imaging. 
  • Does computed tomography or positron emission tomography response after neoadjuvant chemotherapy for resectable non-small-cell lung cancer predict survival? 
  • Does myocardial perfusion imaging provide incremental prognostic information to left ventricular ejection fraction? 
  • Dopamine in amygdala gates limbic processing of aversive stimuli in humans. 
  • Dopamine-modulated aversive emotion processing fails in alcohol-dependent patients. 
  • Dose-dependent effects of radiation therapy on cerebral blood flow, metabolism, and neurocognitive dysfunction. 
  • Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. 
  • Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. 
  • Dramatic increase in autism prevalence parallels explosion of research into its biology and causes. 
  • Early detection of pemetrexed-induced inhibition of thymidylate synthase in non-small cell lung cancer with FLT-PET imaging. 
  • Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor. 
  • Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma. 
  • Early response monitoring of receptor tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma using [F-18]fluorothymidine-positron emission tomography-magnetic resonance. 
  • Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis. 
  • Effect of secondhand smoke on occupancy of nicotinic acetylcholine receptors in brain. 
  • Effectiveness of Florbetapir PET Imaging in Changing Patient Management. 
  • Efficacy of mediastinal lymph node dissection during lobectomy for lung cancer by thoracoscopy and thoracotomy. 
  • Efficient purification and metabolite analysis of radiotracers using high-performance liquid chromatography and on-line solid-phase extraction. 
  • Elective nodal irradiation for locally advanced non-small-cell lung cancer: it's called cancer for a reason. 
  • Enhancing ejection fraction measurement through 4D respiratory motion compensation in cardiac PET imaging. 
  • Estimation of D2-like receptor occupancy by dopamine in the putamen of hemiparkinsonian Monkeys. 
  • Evaluating Alzheimer Disease With Flortaucipir and Florbetapir PET: A Clinical Case Series. 
  • Evaluating dopamine reward pathway in ADHD: clinical implications. 
  • Evaluation of 18F-FDG PET and MRI associations in pediatric diffuse intrinsic brain stem glioma: a report from the Pediatric Brain Tumor Consortium. 
  • Evaluation of 5-(2-(4-pyridinyl)vinyl)-6-chloro-3-(1-methyl-2-(S)-pyrrolidinylmethoxy)pyridine and its analogues as PET radioligands for imaging nicotinic acetylcholine receptors. 
  • Evidence for brain glial activation in chronic pain patients. 
  • Evidence for the treatment of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). 
  • Evolving role of FDG PET/CT in multiple myeloma imaging and management. 
  • Exercise heart rates in patients with hypertrophic cardiomyopathy. 
  • F-18 FDG PET/CT imaging of a hidradenocarcinoma of head and neck. 
  • F-18 FDG PET/CT imaging of a parapharyngeal hemangioma. 
  • F-18 FDG PET/CT imaging of intraventricular germinoma. 
  • F-18 FDG PET/CT imaging of submandibular gland oncocytoma. 
  • F-18-FDG-PET/CT imaging of small cell carcinoma of the colon. 
  • FDG Avidity and Tumor Burden: Survival Outcomes for Patients With Recurrent Breast Cancer. 
  • FDG PET metabolic tumor volume segmentation and pathologic volume of primary human solid tumors. 
  • FDG PET/CT for Management and Assessing Outcomes of Squamous Cell Cancer of the Oral Cavity. 
  • FDG PET/CT imaging of oropharyngeal squamous cell carcinoma: characteristics of human papillomavirus-positive and -negative tumors. 
  • FDG PET/CT in Pancreatic and Hepatobiliary Carcinomas: Value to Patient Management and Patient Outcomes. 
  • FDG PET/CT in Patients With Head and Neck Squamous Cell Carcinoma After Primary Surgical Resection With or Without Chemoradiation Therapy. 
  • FDG PET/CT in patients with HIV. 
  • FDG PET/CT in the management of colorectal and anal cancers. 
  • FDG PET/CT in the management of nasopharyngeal carcinoma. 
  • FDG PET/CT in the management of primary pleural tumors and pleural metastases. 
  • FDG PET/CT interobserver agreement in head and neck cancer: FDG and CT measurements of the primary tumor site. 
  • FDG PET/CT of carcinoma showing thymus-like differentiation. 
  • FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non-Small-Cell Lung Cancer. 
  • FDG volumetric parameters and survival outcomes after definitive chemoradiotherapy in patients with recurrent head and neck squamous cell carcinoma. 
  • FDG-PET assessment of the effect of head and neck radiotherapy on parotid gland glucose metabolism. 
  • FDG-PET for management of cervical and ovarian cancer. 
  • FDG-PET imaging in patients with pulmonary carcinoid tumor. 
  • FDG-PET staging and importance of lymph node SUV in head and neck cancer. 
  • FDG-PET/CT characterization of adrenal nodules: diagnostic accuracy and interreader agreement using quantitative and qualitative methods. 
  • FTO affects food cravings and interacts with age to influence age-related decline in food cravings. 
  • Feasibility of optimizing the dose distribution in lung tumors using fluorine-18-fluorodeoxyglucose positron emission tomography and single photon emission computed tomography guided dose prescriptions. 
  • Fetal gene transfer with lentiviral vectors: long-term in vivo follow-up evaluation in a rat model. 
  • Financial Management Skills in Aging, MCI and Dementia: Cross Sectional Relationship to 18F-Florbetapir PET Cortical β-amyloid Deposition. 
  • Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. 
  • Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. 
  • Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation. 
  • Fluorodeoxyglucose positron emission tomography/computerized tomography in differentiated thyroid cancer management: Importance of clinical justification and value in predicting survival. 
  • Fluorodeoxyglucose-positron-emission tomography imaging of head and neck squamous cell cancer. 
  • Focal F-18 fluoro-deoxy-glucose accumulation in the lung parenchyma in the absence of CT abnormality in PET/CT. 
  • Follow-up FDG PET/CT in Patients With Non-Hodgkin Lymphoma: Value to Clinical Assessment and Patient Management. 
  • Follow-up or Surveillance (18)F-FDG PET/CT and Survival Outcome in Lung Cancer Patients. 
  • Four-dimensional image-based treatment planning: Target volume segmentation and dose calculation in the presence of respiratory motion. 
  • Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies. 
  • Functional and molecular image guidance in radiotherapy treatment planning optimization. 
  • Gender Differences in Radiation Dose From Nuclear Cardiology Studies Across the World: Findings From the INCAPS Registry. 
  • Genetic variation in HTR2A influences serotonin transporter binding potential as measured using PET and [11C]DASB. 
  • Getting on Message: Preventing Alzheimer Disease Through Diet and Exercise. 
  • Giant cell arteritis mimicking infiltrative leptomeningeal disease of the optic nerves. 
  • Greater nicotinic acetylcholine receptor density in smokers than in nonsmokers: a PET study with 2-18F-FA-85380. 
  • Head and neck PET/CT: therapy response interpretation criteria (Hopkins Criteria)-interreader reliability, accuracy, and survival outcomes. 
  • Head and neck cancer as a model for advances in imaging prognosis, early assessment, and posttherapy evaluation. 
  • Head and neck cancer: dedicated FDG PET/CT protocol for detection--phantom and initial clinical studies. 
  • Hemispheric asymmetry of sulcus-function correspondence: quantization and developmental implications. 
  • Hibernoma: 18F FDG PET/CT imaging. 
  • Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. 
  • Hodgkin lymphoma, version 2.2015. 
  • Hospice Admission and Survival After 18F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry. 
  • How Accurately Do Patients and Their Care Partners Report Results of Amyloid-β PET Scans for Alzheimer's Disease Assessment? 
  • Human functional neuroimaging in nicotine and tobacco research: basics, background, and beyond. 
  • I-131, I-123, and F-18 FDG-PET imaging in a patient with diffuse sclerosing variant of papillary thyroid cancer. 
  • Identification of distant metastases with PET-CT in patients with suspected recurrent head and neck cancer. 
  • Identification of distant metastases with positron-emission tomography-computed tomography in patients with previously untreated head and neck cancer. 
  • Imaging biomarker roadmap for cancer studies. 
  • Imaging for assessment of radiation-induced normal tissue effects. 
  • Imaging genetics of brain longevity and mental wellness: the next frontier? 
  • Imaging of musculoskeletal bacterial infections by [124I]FIAU-PET/CT. 
  • Imaging of primary and secondary renal lymphoma. 
  • Imaging tumors of the penis and urethra. 
  • Imaging-guided preoperative hookwire localization of nonpalpable extramammary lesions. 
  • Impact of concurrent diagnostic level CT with PET/CT on the utilization of stand-alone CT and MRI in the management of head and neck cancer patients. 
  • Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging. 
  • Impact of point spread function reconstruction on quantitative 18F-FDG-PET/CT imaging parameters and inter-reader reproducibility in solid tumors. 
  • Impact of pre-operative positron emission tomography in gallbladder cancer. 
  • Impact of short access nicotine self-administration on expression of α4β2* nicotinic acetylcholine receptors in non-human primates. 
  • Impact of ¹⁸F-florbetapir PET imaging of β-amyloid neuritic plaque density on clinical decision-making. 
  • Impact on Patient Management of [18F]-Fluorodeoxyglucose-Positron Emission Tomography (PET) Used for Cancer Diagnosis: Analysis of Data From the National Oncologic PET Registry. 
  • Impaired glucose tolerance in midlife and longitudinal changes in brain function during aging. 
  • Improved cardiac risk assessment with noninvasive measures of coronary flow reserve. 
  • Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling. 
  • Improving outcomes in advanced DLBCL: systemic approaches and radiotherapy. 
  • In Reply to Giron et al. 
  • In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. 
  • In vivo noninvasive detection of Brown Adipose Tissue through intermolecular zero-quantum MRI. 
  • In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma. 
  • Incidence and patterns of neuraxis metastases in children with diffuse pontine glioma. 
  • Incidental, subsolid pulmonary nodules at CT: etiology and management. 
  • Increased Glutaminolysis Marks Active Scarring in Nonalcoholic Steatohepatitis Progression. 
  • Increasing PET Use in Small Cell Lung Cancer: Survival Improvement and Stage Migration in the VA Central Cancer Registry. 
  • Increasing uptake time in FDG-PET: standardized uptake values in normal tissues at 1 versus 3 h. 
  • Individual Differences in Dopamine Are Associated with Reward Discounting in Clinical Groups But Not in Healthy Adults. 
  • Individual differences in dopamine D2 receptor availability correlate with reward valuation. 
  • Influence of filter choice on 18F-FDG PET segmentation accuracy determined using generalized estimating equations. 
  • Initial Performance of NI-RADS to Predict Residual or Recurrent Head and Neck Squamous Cell Carcinoma. 
  • Integration of PET/MR Hybrid Imaging into Radiation Therapy Treatment. 
  • Intended Versus Inferred Treatment After 18F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry. 
  • Interesting image. F-18 fluorodeoxyglocose positron emission tomography/computed tomography in the diagnosis of chronic myopathic sarcoidosis. 
  • Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? 
  • Interpretation and reporting of positron emission tomography-computed tomographic scans. 
  • Interreader agreement and variability of FDG PET volumetric parameters in human solid tumors. 
  • Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). 
  • Intra-Target Microdosing - A Novel Drug Development Approach: Proof of Concept, Safety, and Feasibility Study in Humans. 
  • Intra-reader reliability of FDG PET volumetric tumor parameters: effects of primary tumor size and segmentation methods. 
  • Intraarterial Microdosing: A Novel Drug Development Approach, Proof-of-Concept PET Study in Rats. 
  • Intratherapy or Posttherapy FDG PET or FDG PET/CT for Patients With Head and Neck Cancer: A Systematic Review and Meta-analysis of Prognostic Studies. 
  • Intratreatment Response Assessment With 18F-FDG PET: Correlation of Semiquantitative PET Features With Pathologic Response of Esophageal Cancer to Neoadjuvant Chemoradiotherapy. 
  • Is follow-up CT imaging of the chest and abdomen necessary after preoperative neoadjuvant therapy in rectal cancer patients without evidence of metastatic disease at diagnosis? 
  • Ivory vertebra on 18F-sodium fluoride scan: an old sign in a new modality. 
  • Journal Club: incidental thyroid nodules detected at imaging: can diagnostic workup be reduced by use of the Society of Radiologists in Ultrasound recommendations and the three-tiered system? 
  • Kaposi sarcoma after bilateral lung transplantation. 
  • Kinetics of brain nicotine accumulation in dependent and nondependent smokers assessed with PET and cigarettes containing 11C-nicotine. 
  • Lack of consistent sex differences in D-amphetamine-induced dopamine release measured with [¹⁸ F]fallypride PET. 
  • Late Gadolinium Enhancement Cardiac Magnetic Resonance Tissue Characterization for Cancer-Associated Cardiac Masses: Metabolic and Prognostic Manifestations in Relation to Whole-Body Positron Emission Tomography. 
  • Linking dementia research to policy: an example using fluorodeoxyglucose positron emission tomography for the diagnosis of Alzheimer's dementia and mild cognitive impairment. 
  • Linking variability in brain chemistry and circuit function through multimodal human neuroimaging. 
  • Liver SULmean at FDG PET/CT: interreader agreement and impact of placement of volume of interest. 
  • Liver standardized uptake value corrected for lean body mass at FDG PET/CT: effect of FDG uptake time. 
  • Long-term stimulant treatment affects brain dopamine transporter level in patients with attention deficit hyperactive disorder. 
  • Low-dose consolidation radiation therapy for early stage unfavorable Hodgkin lymphoma. 
  • Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. 
  • Lung Cancers Associated With Cystic Airspaces: Natural History, Pathologic Correlation, and Mutational Analysis. 
  • MAPT rs242557 variant is associated with hippocampus tau uptake on 18F-AV-1451 PET in non-demented elders. 
  • MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis. 
  • MR imaging and PET/CT in diagnosis and management of multiple myeloma. 
  • MR-PET co-registration in upper abdominal imaging: quantitative comparison of two different T1-weighted gradient echo sequences: initial observations. 
  • MR-PET evaluation of 1-month post-ablation therapy for hepatocellular carcinoma: preliminary observations. 
  • MRI Evaluation of the Response of Rectal Cancer to Neoadjuvant Chemoradiation Therapy. 
  • MRI for the assessment of myocardial viability. 
  • Mapping the effects of ApoE4, age and cognitive status on 18F-florbetapir PET measured regional cortical patterns of beta-amyloid density and growth. 
  • Measurement of the alpha4beta2* nicotinic acetylcholine receptor ligand 2-[(18)F]Fluoro-A-85380 and its metabolites in human blood during PET investigation: a methodological study. 
  • Mechanistic Insights into Sympathetic Neuronal Regeneration: Multitracer Molecular Imaging of Catecholamine Handling After Cardiac Transplantation. 
  • Melanoma-associated retinopathy: a presenting sign of metastatic disease. 
  • Mesolimbic dopamine D2 receptors and neural representations of subjective value. 
  • Meta-analysis: the detection of pancreatic malignancy with positron emission tomography. 
  • Meta-iodobenzylguanidine and analogues: chemistry and biology. 
  • Metastatic melanoma to the heart. 
  • Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with attention deficit hyperactivity disorder. 
  • Midlife adiposity predicts earlier onset of Alzheimer's dementia, neuropathology and presymptomatic cerebral amyloid accumulation. 
  • Modeling pathologic response of esophageal cancer to chemoradiation therapy using spatial-temporal 18F-FDG PET features, clinical parameters, and demographics. 
  • Molecular Imaging and Precision Medicine in Head and Neck Cancer. 
  • Molecular Imaging in the Head and Neck: Diagnosis and Therapy. 
  • Molecular PET imaging in multicenter Alzheimer's therapeutic trials: current trends and implementation strategies. 
  • Molecular imaging for depressive disorders. 
  • Molecular imaging in Alzheimer's disease. 
  • Molecular imaging of hypoxia. 
  • Motivation deficit in ADHD is associated with dysfunction of the dopamine reward pathway. 
  • Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. 
  • Multimodal and Multiscale Deep Neural Networks for the Early Diagnosis of Alzheimer's Disease using structural MR and FDG-PET images. 
  • Multisphere phantom and analysis algorithm for PET image quality assessment. 
  • Myocardial Energetics in Heart Failure With Preserved Ejection Fraction. 
  • Myocardial Involvement in Patients With Histologically Diagnosed Cardiac Sarcoidosis: A Systematic Review and Meta-Analysis of Gross Pathological Images From Autopsy or Cardiac Transplantation Cases. 
  • NIDA522131, a new radioligand for imaging extrathalamic nicotinic acetylcholine receptors: in vitro and in vivo evaluation. 
  • Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates. 
  • New advances in focal therapy for early stage prostate cancer. 
  • New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer. 
  • Nuclear cardiology practice and associated radiation doses in Europe: results of the IAEA Nuclear Cardiology Protocols Study (INCAPS) for the 27 European countries. 
  • Oncogene pathway activation in mammary tumors dictates FDG-PET uptake. 
  • Oncologic 18F-FDG PET/CT: referring physicians' point of view. 
  • PET and brain tumor image fusion. 
  • PET appearance of tuberculous empyema necessitans. 
  • PET of hypoxia and perfusion with 62Cu-ATSM and 62Cu-PTSM using a 62Zn/62Cu generator. 
  • PET scanning in mild cognitive impairment. 
  • PET with 62Cu-ATSM and 62Cu-PTSM is a useful imaging tool for hypoxia and perfusion in pulmonary lesions. 
  • PET with Fluorodeoxyglucose F 18/Computed Tomography in the Clinical Management and Patient Outcomes of Esophageal Cancer. 
  • PET-CT: current applications and new developments in the thorax. 
  • PET-based primary tumor volumetric parameters and survival of patients with non-small cell lung carcinoma. 
  • PET/CT imaging and human papilloma virus-positive oropharyngeal squamous cell cancer: evolving clinical imaging paradigm. 
  • PET/CT in the management of thyroid cancers. 
  • PET/CT of cancer patients: part 1, pancreatic neoplasms. 
  • PET/CT of cancer patients: part 2, deformable registration imaging before and after chemotherapy for radiation treatment planning in head and neck cancer. 
  • PET/CT today and tomorrow in veterinary cancer diagnosis and monitoring: fundamentals, early results and future perspectives. 
  • PET/CT: Adding Value to Patient Outcomes and Health Care Delivery. 
  • PET/CT: Defining Value to Patients and Health Systems. 
  • Parotid gland tumors: preliminary data for the value of FDG PET/CT diagnostic parameters. 
  • Partial-volume correction increases estimated dopamine D2-like receptor binding potential and reduces adult age differences. 
  • Patient management after noninvasive cardiac imaging results from SPARC (Study of myocardial perfusion and coronary anatomy imaging roles in coronary artery disease). 
  • Pattern of failure in anaplastic glioma patients with an IDH1/2 mutation. 
  • Patterns of recurrence after trimodality therapy for esophageal cancer. 
  • Perceived misinterpretation rates in oncologic 18F-FDG PET/CT studies: a survey of referring physicians. 
  • Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate. 
  • Pharmacological and toxicological evaluation of 2-fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-F-A-85380), a ligand for imaging cerebral nicotinic acetylcholine receptors with positron emission tomography. 
  • PhytoBeta imager: a positron imager for plant biology. 
  • Positron emission tomography combined with diagnostic chest computed tomography enhances detection of regional recurrence after stereotactic body radiation therapy for early stage non-small cell lung cancer. 
  • Positron emission tomography in hepatobiliary and pancreatic malignancies: a review. 
  • Positron emission tomography in radiation treatment planning: the potential of metabolic imaging. 
  • Posttreatment Imaging in Patients with Head and Neck Cancer without Clinical Evidence of Recurrence: Should Surveillance Imaging Extend Beyond 6 Months? 
  • Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. 
  • Potential of immuno-positron emission tomography for tumor imaging and immunotherapy planning. 
  • Practical approach to diagnostic CT combined with PET. 
  • Preclinical evaluation of 18F-JNJ41510417 as a radioligand for PET imaging of phosphodiesterase-10A in the brain. 
  • Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. 
  • Predictive and prognostic role of functional imaging of head and neck squamous cell carcinomas. 
  • Preliminary validation of varicella zoster virus thymidine kinase as a novel reporter gene for PET. 
  • Primary surgery versus chemoradiation in the treatment of IB2 cervical carcinoma: a cost effectiveness analysis. 
  • Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. 
  • Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data. 
  • Principles and techniques of radiation therapy for esophageal and gastroesophageal junction cancers. 
  • Prognosis of conversion of mild cognitive impairment to Alzheimer's dementia by voxel-wise Cox regression based on FDG PET data. 
  • Prognostic Value of FDG PET/CT-Derived Parameters in Pancreatic Adenocarcinoma at Initial PET/CT Staging. 
  • Prognostic modeling for patients with colorectal liver metastases incorporating FDG PET radiomic features. 
  • Prognostic significance of parameters derived from co-registered 18F-fluorodeoxyglucose PET and contrast-enhanced MRI in patients with high-grade glioma. 
  • Prognostic value of 3'-deoxy-3'-18F-fluorothymidine ([(18)F] FLT PET) in patients with recurrent malignant gliomas. 
  • Prognostic value of PET myocardial perfusion imaging in obese patients. 
  • Prognostic value of Rb-82 positron emission tomography myocardial perfusion imaging in coronary artery bypass patients. 
  • Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. 
  • Prognostic value of midtreatment FDG-PET in oropharyngeal cancer. 
  • Prognostic value of stress myocardial perfusion positron emission tomography: results from a multicenter observational registry. 
  • Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. 
  • Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases. 
  • Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer. 
  • Quantification of alpha4beta2* nicotinic receptors in the rat brain with microPET and 2-[18F]F-A-85380. 
  • Quantification of nicotinic acetylcholine receptors in the human brain with PET: bolus plus infusion administration of 2-[18F]F-A85380. 
  • Quantitative effects of contrast enhanced CT attenuation correction on PET SUV measurements. 
  • Quantitative imaging in oncology patients: Part 1, radiology practice patterns at major U.S. cancer centers. 
  • Quantitative imaging in oncology patients: Part 2, oncologists' opinions and expectations at major U.S. cancer centers. 
  • R. Edward Coleman, MD, 1943-2012. 
  • Radiofrequency ablation for primary lung cancer and pulmonary metastases. 
  • Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment. 
  • Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs. 
  • Radiology quiz case 2. Docetaxel (Taxotere)-induced photosensitivity. 
  • Radiosensitive orbital metastasis as presentation of occult colonic adenocarcinoma. 
  • Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. 
  • Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. 
  • Reasons Associated with Total Thyroidectomy as Initial Surgical Management of an Indeterminate Thyroid Nodule. 
  • Recent developments in predicting thyroid malignancy. 
  • Recommendations on the use of 18F-FDG PET in oncology. 
  • Redistribution of health care costs after the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2005. 
  • Reduced effects of age on dopamine D2 receptor levels in physically active adults. 
  • Reduced serotonin receptors and transporters in normal aging adults: a meta-analysis of PET and SPECT imaging studies. 
  • Regional Amyloid-β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer's Dementia. 
  • Regional brain activity correlates of nicotine dependence. 
  • Regional cerebral blood flow and metabolic rate in persistent Lyme encephalopathy. 
  • Regional cerebral glucose metabolism differentiates danger- and non-danger-based traumas in post-traumatic stress disorder. 
  • Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials. 
  • Repeatability of hypoxia PET imaging using [¹⁸F]HX4 in lung and head and neck cancer patients: a prospective multicenter trial. 
  • Reply to "Prognostic Value of Fluorodeoxyglucose-Positron Emission Tomography". 
  • Reply to M.S. Hofman et al. 
  • Reply: Pharmacokinetic and Pharmacodynamic Modifiers of EF5 Uptake and Binding. 
  • Retinal microvasculature changes in amyloid-negative subcortical vascular cognitive impairment compared to amyloid-positive Alzheimer's disease. 
  • Safety of radial arterial catheterization in PET research subjects. 
  • Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. 
  • Science to practice: Molecular targeting with SPECT/CT and MR imaging in oncology--integration of functional and structural imaging. 
  • Selecting a noninvasive imaging study after an inconclusive exercise test. 
  • Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. 
  • Sex and APOE ε4 genotype modify the Alzheimer's disease serum metabolome. 
  • Sex-specific effects of cigarette mentholation on brain nicotine accumulation and smoking behavior. 
  • Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy. 
  • Spatiotemporal distribution modeling of PET tracer uptake in solid tumors. 
  • Spontaneous Eye Blink Rate (EBR) Is Uncorrelated with Dopamine D2 Receptor Availability and Unmodulated by Dopamine Agonism in Healthy Adults. 
  • Stage migration, selection bias, and survival associated with the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2003. 
  • Staging chest computed tomography and positron emission tomography in patients with pancreatic adenocarcinoma: utility or futility? 
  • Superior prognostic utility of gross and metabolic tumor volume compared to standardized uptake value using PET/CT in head and neck squamous cell carcinoma patients treated with intensity-modulated radiotherapy. 
  • Synthesis and biological evaluation of an 123I-labeled bicyclic nucleoside analogue (BCNA) as potential SPECT tracer for VZV-tk reporter gene imaging. 
  • Synthesis and evaluation of 18F- and 11C-labeled phenyl-galactopyranosides as potential probes for in vivo visualization of LacZ gene expression using positron emission tomography. 
  • Synthesis and evaluation of 18F-labeled benzylguanidine analogs for targeting the human norepinephrine transporter. 
  • Synthesis and evaluation of 4-[18F]fluoropropoxy-3-iodobenzylguanidine ([18F]FPOIBG): A novel 18F-labeled analogue of MIBG. 
  • Synthesis and preliminary evaluation of 18F- or 11C-labeled bicyclic nucleoside analogues as potential probes for imaging varicella-zoster virus thymidine kinase gene expression using positron emission tomography. 
  • Synthesis and structure-activity relationship of a novel series of aminoalkylindoles with potential for imaging the neuronal cannabinoid receptor by positron emission tomography. 
  • Synthesis, fluorine-18 radiolabeling, and in vitro characterization of 1-iodophenyl-N-methyl-N-fluoroalkyl-3-isoquinoline carboxamide derivatives as potential PET radioligands for imaging peripheral benzodiazepine receptor. 
  • Synthetic positron emission tomography-computed tomography images for use in perceptual studies. 
  • Task Group 174 Report: Utilization of [18 F]Fluorodeoxyglucose Positron Emission Tomography ([18 F]FDG-PET) in Radiation Therapy. 
  • Technical considerations in radiation therapy for gastroesophageal junction cancer. 
  • Temporoparietal hypometabolism in frontotemporal lobar degeneration and associated imaging diagnostic errors. 
  • The Alzheimer structural connectome: changes in cortical network topology with increased amyloid plaque burden. 
  • The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory. 
  • The Current and Evolving Role of PET in Personalized Management of Lung Cancer. 
  • The Role of Positron Emission Tomography/Computed Tomography in Management and Prediction of Survival in Pancreatic Cancer. 
  • The added value of 18F-FDG PET/CT for evaluation of patients with esthesioneuroblastoma. 
  • The development of a population of 4D pediatric XCAT phantoms for imaging research and optimization. 
  • The immune response of the human brain to abdominal surgery. 
  • The impact of radiation therapy in patients with diffuse large B-cell lymphoma with positive post-chemotherapy FDG-PET or gallium-67 scans. 
  • The neurobiology of individual differences in complex behavioral traits. 
  • The role of PET/CT in the management of cervical cancer. 
  • The role of adaptive and functional imaging modalities in radiation therapy: approach and application from a radiation oncology perspective. 
  • The triangular intermuscular space as a site of lymph node metastasis in melanoma of the back. 
  • The utility of F-18 fluorodeoxyglucose whole body PET imaging for determining malignancy in cystic lesions of the pancreas. 
  • The utility of FDG-PET for assessing outcomes in oligometastatic cancer patients treated with stereotactic body radiotherapy: a cohort study. 
  • The value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma. 
  • The value of diagnostic medical imaging. 
  • The year in cardiovascular surgery. 
  • Therapeutic tools in pancreatic cancer. 
  • Therapy Response Assessment and Patient Outcomes in Head and Neck Squamous Cell Carcinoma: FDG PET Hopkins Criteria Versus Residual Neck Node Size and Morphologic Features. 
  • Thoracic imaging. 
  • Thyroid carcinoma: the surgeon's perspective. 
  • Tracking radiation exposure of patients. 
  • Transgastric retrograde endoscopic ultrasound sampling of a mediastinal mass in a patient with radiation-induced trismus. 
  • Treatment for tobacco dependence: effect on brain nicotinic acetylcholine receptor density. 
  • Tumor blood flow measured by PET dynamic imaging of first-pass 18F-FDG uptake: a comparison with 15O-labeled water-measured blood flow. 
  • Tumor blood flow measured by perfusion computed tomography and 15O-labeled water positron emission tomography: a comparison study. 
  • Tumor necrosis and cavitation after stereotactic body radiation therapy. 
  • Two-time-point FDG PET/CT: liver SULmean repeatability. 
  • Up-regulation of nicotinic acetylcholine receptors in menthol cigarette smokers. 
  • Use of 18F-FDG PET/CT as a predictive biomarker of outcome in patients with head-and-neck non-squamous cell carcinoma. 
  • Use of 18F-Fludeoxyglucose-Positron Emission Tomography/Computed Tomography for Patient Management and Outcome in Oropharyngeal Squamous Cell Carcinoma: A Review. 
  • Use of Multimodality Imaging in Diagnosing Invasive Fungal Diseases of the Heart. 
  • Use of florbetapir-PET for imaging beta-amyloid pathology. 
  • Using FDG-PET activity as a surrogate for tumor cell density and its effect on equivalent uniform dose calculation. 
  • Using FDG-PET to measure early treatment response in head and neck squamous cell carcinoma: quantifying intrinsic variability in order to understand treatment-induced change. 
  • Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. 
  • Using the 3-tiered system for categorizing workup of incidental thyroid nodules detected on CT, MRI, or PET/CT: how many cancers would be missed? 
  • Utility of FDG PET/CT in inflammatory cardiovascular disease. 
  • Utility of functional imaging in prediction or assessment of treatment response and prognosis following thermotherapy. 
  • Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma. 
  • Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma. 
  • Validation of an extracerebral reference region approach for the quantification of brain nicotinic acetylcholine receptors in squirrel monkeys with PET and 2-18F-fluoro-A-85380. 
  • Validation of consensus panel diagnosis in dementia. 
  • Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas. 
  • Value of Fluorodeoxyglucose PET/Computed Tomography Patient Management and Outcomes in Thyroid Cancer. 
  • Value of PET/CT in the management of primary hepatobiliary tumors, part 2. 
  • Value of fluoro-2-deoxy-D-glucose-positron emission tomography for detecting metastatic lesions in head and neck cancer. 
  • Variable-time positron emission tomography leg protocol to equalize noise for positron emission tomography/computed tomography acquisitions. 
  • Variations in use of PET among Medicare beneficiaries with non-small cell lung cancer, 1998-2007. 
  • Ventilation defects observed with hyperpolarized 3He magnetic resonance imaging in a mouse model of acute lung injury. 
  • Ventral striatal dopamine transporter availability is associated with lower trait motor impulsivity in healthy adults. 
  • Vulnerable plaque intervention: State of the art. 
  • Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. 
  • When is a biopsy-proven diagnosis necessary before stereotactic ablative radiotherapy for lung cancer?: A decision analysis. 
  • Willingness to Undergo a Risky Treatment to Improve Cognition Among Persons With Cognitive Impairment Who Received an Amyloid PET Scan. 
  • [18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy. 
  • [18F]Fluoro-L-dopa PET/CT in congenital hyperinsulinism. 
  • [18F]fluorodeoxyglucose-positron emission tomography in patients with medulloblastoma. 
  • ¹⁸F-FDG PET/CT and Colorectal Cancer: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management. 
• 

  Keywords of People

  • Chitneni, Satish K., Associate Professor in Radiology, Radiology
  • Curtis, Lesley H., Professor in Population Health Sciences, Medicine, General Internal Medicine
  • Esclamado, Ramon Mitra, Professor Emeritus of Head and Neck Surgery and Communication Sciences, Head and Neck Surgery & Communication Sciences
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Palmer, Gregory M., Associate Professor of Radiation Oncology, Radiation Oncology
  • Patz Jr., Edward F., James and Alice Chen Distinguished Professor of Radiology, Pathology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering
  • Segars, William Paul, Associate Professor in Radiology, Radiology
  • Sullivan, Daniel Carl, Professor Emeritus of Radiology, Radiology
  • Turkington, Timothy Garvey, Associate Professor in Radiology, Radiology
  • Turner, Dennis Alan, Professor of Neurosurgery, Biomedical Engineering